The Wyss Institute’s Brain Targeting Program (BTP), co-led by James Gorman, M.D., Ph.D. and Donald Ingber, M.D., Ph.D., is developing brain delivery technologies that enable development of safer and more effective brain-targeted therapeutics for diverse brain diseases. Our brain delivery platform enables these therapeutic advances by dramatically improving transport of drugs across the blood-brain barrier (BBB) into the brain. We are looking for a talented Scientist to support the discovery and validation of our antibody brain shuttles and to lead the development of our brain shuttle-mediated oligonucleotide platform. Reporting to the Principal Scientist, you will work closely with our team using both in vitro cellular systems and in vivo humanized mouse models to optimize oligonucleotide delivery. [65751BR]